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Abstract 
 
Objective. Assessment of intracranial vessels includes transcranial doppler (TCD). TCD 
performance requires intact temporal acoustic windows (TAW). Failure of TAW (TAWF) is 
present in 8-20% of people. There have been no reports on TAWF in rheumatoid arthritis (RA). 
Methods.  Altogether 62 female RA patients were included. Among them, 20 were MTX-
treated and biologic-free, 20 received infliximab and 22 tocilizumab. The controls included 60 
non-RA women. TAWF, temporal bone thickness and texture were determined by ultrasound 
and CT. BMD and T-scores of multiple bones were determined by DEXA. Several bone 
biomarkers were assessed by ELISA. 
 Results. In RA, 54.8% of the patients had TAWF on at least one side. Neither TAW could be 
identified in 34% of RA subjects. In contrast, only 20.0% of control subjects had TAWF on 
either or both sides (p<0.001). In RA vs controls, 53.0% vs 2.9% of subjects exerted the trilayer, 
“sandwich-like” structure of TAW (p<0.001). Finally, in RA vs controls, the mean temporal 
bone thickness values of the right TAW were 3.58±1.43 mm vs 2.92±1.22 mm (p=NS), while 
those of the left TAW were 4.16±1.56 mm vs 2.90±1.16 mm (p=0.001). There was close 
association between TAWF, bone thickness and texture (p<0.05). These TAW parameters all 
correlated with age, however TAW failure and texture also correlated with serum 
osteoprotegerin. TAW bone thickness inversely correlated with hip BMD (p<0.05). 
Conclusions.  TAWF, thicker and heterogeneous temporal bones were associated with RA. 
These features have been associated with bone loss and OPG production. Bone loss seen in RA 
may result in OPG release and stimulation of bone formation around TAW. 
 
  
 Introduction 
 
 Rheumatoid arthritis (RA) is a chronic inflammatory rheumatic disease affecting the 
joints and other organ systems [1]. Accelerated atherosclerosis and increased stroke morbidity 
and mortality have been associated with RA [2-4], however, no systematic evaluation of 
intracranial circulation has yet been performed.  
 Intracranial vessels, primarily the middle cerebral arteries (MCA) are assessed by 
transcranial doppler (TCD). With this technique, cerebral arteries are studied through relatively 
thin bone windows [5]. Approximately 8-20% of healthy individuals have inadequate temporal 
acoustic windows (TAW) [6-8]. This is also defined as TAW failure (TAWF) [9]. The thickness 
and texture of temporal bone may also influence TAW detectability [9]. There is an increased 
prevalence of in TAWF in females and in elderly people [6, 7]. In a stroke study, TCD signals 
could not be adequately obtained due to TAWF in 34% of patients. TAWF, bone thickness and 
inhomogeneous texture correlated with age and with each other [9].  
 In stroke patients, TAWF did not correlate with vertebral, femoral or total bone mineral 
density (BMD). However, heterogeneous temporal bone texture correlated with lower BMD 
[9]. We have not found any reports on possible associations between TAWF, temporal bone 
texture and thickness and various bone markers. 
.  Here we assessed the availability of TAWs in patients with RA. We used a selected 
healthy population without any known cardiovascular (CV) risk as control group. We 
determined TAWF, temporal bone thickness and texture. As RA has been associated with 
increased bone turnover and generalized bone loss [10, 11], which could affect bone deposition 
around the TAW, we also studied the features of TAW in relation to BMD and bone markers. 
As the examiner has to examine both left and right cerebral arteries during TCD assessment, it 
is also important to assess TAW on both sides. Furthermore, there may be anatomical 
differences between left and right side arteries, therefore, we also wished to compare TAW 
features on left vs right side. To our knowledge, this is the very first study assessing TAWs, 
TAWF and characteristics of the temporal bone in RA. 
 
 
Patients and methods 
 
Patients and controls 
 
 Sixty-two consecutive RA patients were recruited for the study. The major 
characteristics of the patients are shown in Table 1. All patients were females, their mean age 
was 60.7±9.5 (range: 27-78) years. Mean disease duration was 11.5±7.6 (range: 1-36) years. 
Altogether 75% were IgM rheumatoid factor (RF) positive, and 75% were anti-CCP positive. 
Among these patients, 20 were biologic-free. They had been receiving MTX for a mean 6.8±4.7 
(range: 1-15) years in a mean dose of 14.1±4.5 (range: 5-20) mg per week. Altogether 42 
patients had been receiving biologics for a mean duration of 5.2±1.9 (range: 1-8) years. In 
addition, 32 patients were on low-dose corticosteroids. However, they had been receiving it in 
a stable dose for at least six months. 
 A cohort of 60 non-RA women were chosen as control group. Their mean age was 
56.3±10.9 (range: 29-90) years. The existence of TAWF was determined in these subjects. 
None of these individuals had hypertension, known cardiovascular or cerebrovascular disease. 
The thickness and bone structure of TAWs were assessed in a subset (n=35) of this control 
population. In this subset, the mean age was 53.7±4.0 (range: 48-60) years. 
 The Borsod County Teaching Hospital IRB approved this study (No. 13/2016). 
 
Determination of temporal windows 
 
 Before the TCD assessment was carried out by ultrasound (not included in this paper), 
the ultrasonographer (M.S., a single observer) determined whether the right and left TAW were 
detectable or not.  TAWF was determined in 62 RA patients and 60 control subjects. A TAW 
score was also established. A score of 0, 1 or 2 indicated TAWF on both sides, either side or 
none of the sides, respectively.  
Furthermore, the thickness and structure (ʺcondenseʺ cortical bone or ʺsandwichʺ-like 
trilayer) of TAWs were determined by computed tomography (CT) (Somatom Definition AS, 
64-slice, Siemens, Germany) in 43 RA patients and 35 healthy controls. The instrument was set 
to bone window and native images of 2 mm thick slices were evaluated. The thickness of TAW 
expressed in mm was measured at a point 3 cm anterior to the earlobe. With respect to the 
texture, either a thin temporal bone with a condense, homogenous cortical structure, or a thicker, 
heterogenous trilayer (cortical-diploe-cortical) pattern could be detected around the TAW [9]. 
(Bone density was not specifically assessed, however, it is always higher in the compact cortical 
bone, and lower in the thicker trilayer.) 
 
Bone densitometry and bone markers 
 
 BMD and T-scores of the lumbar L1 and L2-4 vertebrae, femoral neck and total hip 
were assessed by DEXA (Hologic 010-0575, Bedford, MA, USA). 
 Among bone biomarkers, serum calcium and phosphate were determined by routine 
laboratory methods. Serum osteocalcin (OC; normal: <41 μg/l), β-CrossLaps (CTX; normal: 
<0.57 μg/l), P1NP (normal: <75 μg/l), 25-hydroxy-vitamin D3 (25-OH-vitD3; normal: >75 
nmol/l), parathormon (PTH; normal: 1.6-6.9 pmol/l), osteoprotegerin (OPG; median: 2.7 
pmol/l, normal: to be determined [TBD] locally in the lab), sclerostin (SOST; median: 24.1 
pmol/l, normal: TBD), free soluble RANK ligand (sRANKL; median: 0.37 pmol/l in females, 
normal: TBD) were determined by ELISA (Biomedica, Vienna, Austria). OPG/sRANKL ratios 
were also calculated. 
 
Statistical analysis  
 
The statistical analysis was processed with IBM SPSS 22 software.  The data are 
expressed as the mean ± SD and frequencies and percentages. Continuous variables were 
evaluated by paired two-tailed t-test and Wilcoxon test. Nominal variables were compared 
between groups using the chi-squared or Fisher’s exact test, as appropriate. Simple correlations 
were determined by Spearman’s analysis. Multiple linear regression using the stepwise method 
was used to determine correlations and independent associations between parameters. TAW 
parameters were the dependent variables and several other clinical and laboratory parameters 
were independent variables. The B (+95% CI) regression coefficient indicated independent 
association between the dependent and independent variable during changes. P values < 0.05 
were considered significant. The SPSS 22.0 software was used for statistical analysis. 
 Results 
 
Detectability, texture and thickness of TAW in RA versus controls 
 
 In RA, 34 out of the 62 patients (54.8%) had TAWF on at least one side. (Neither TAW 
could be identified in 34% of RA subjects.) In contrast, only 20.0% of control subjects had 
TAWF on either or both sides (p<0.001) (Table 2).  
 TAW texture could be assessed in 43 RA patients and 35 controls. In control subjects, 
only one out of 35 subjects exerted the “sandwich-like” structure on either sides (2.9%). On the 
other hand, in RA, 53.0% of patients exerted this trilayer texture on at least one side (p<0.001) 
(Table 2). Thus, while only less than 3% of healthy subjects have sandwich TAW structure, 
one-third to more than half of RA patients may exert this feature (Table 2).  
 Bone thickness around TAW could be assessed also in 43 RA patients and 35 controls. 
In RA vs controls, the mean temporal bone thickness values of the right TAW were 3.58±1.43 
mm vs 2.92±1.22 mm (p=NS), while those of the left TAW were 4.16±1.56 mm vs 2.90±1.16 
mm (p=0.001) (Table 2).  
 
Correlations between TAW features and disease markers in RA  
  
 First, the various TAW parameters were correlated with each other (Table 3). There 
have been significant associations between TAWF, thickness and structure. In the RA cohort 
(n=62), the absence of right TAW was significantly associated with increased thickness 
(R=0.811, p<0.001) and the sandwich-like texture of the right TAW (R=0.712, p<0.001). 
Similar observations were made with respect to the left TAWs (thickness: R=0.768, p<0.01, 
texture: R=0.791, p<0.01). The thickness of right and left TAWs also correlated with the 
heterogeneous texture on the corresponding sides (right: R=0.569, p<0.01, left: R=0.457, 
p=0.02) (Table 3).  
Binary logistic regression analysis was performed in order to determine correlations 
between TAW characteristics (dependent variables) and other clinical and laboratory 
parameters (independent variables) (Tables 4 and 5). In the linear regression analysis, TAWF 
(lower TAW scores) on both sides (p=0.007) significantly correlated with age. Interestingly, 
left TAWF was associated with OPG levels (p=0.012) (Table 4). In addition, this texture on 
right (p=0.045) or left (p=0.016) side exerted significant correlation with OPG (Table 3). Right 
(p=0.025) or left (p=0.007) TAW bone thickness correlated with age. Finally, TAW thickness 
on the left side correlated with femoral neck and total hip bone loss (Table 4). 
 Multiple regression analysis was performed to determine independent prognostic factors 
for TAWF in RA. Age (p=0.026) and serum OPG levels (p=0.012) were independent predictors 
of left TAWF. Age was also a predictor of sandwich-like texture of the left TAW (p=0.007) 
(Table 5).  
  
Discussion 
 
 TAW accessibility is essential to perform TCD. Unfortunately, in the general 
population, TAWF is found in about 8-20% of individuals [6-8]. In stroke patients TAWF may 
be more common (34%) [9]. The texture and the thickness of temporal bone may also be of 
importance. TAWF has been associated with temporal bone inhomogeneity and increased 
thickness [9]. The characteristics of TAW have not yet been studied in RA patients so we do 
not have any reported data for comparison. 
 Here we performed a study carried out on 62 RA patients in comparison to a population 
of 60 non-RA individuals undergoing routine TCD screening. In RA patients, TAWF was 
observed on either or both sides in 34-53% of patients and in 13-20% of controls. The frequency 
of TAWF was significantly higher compared to controls and was also higher than what was 
reported by others in the general population [6]. 
 While only one control subject (3%) had the heterogeneous temporal bone structure, 
this phenomenon was observed in 53-60% of RA patients. Bone inhomogeneity has also been 
described in stroke patients [9].  
 The temporal bone was also thicker in RA patients (3.6-4.6 mm) compared to controls 
(2.9 mm). Stroke patients may also exert thicker temporal bones [9].  
 We observed significant paired correlations between TAWF, temporal bone 
heterogeneous texture and thickness on both sides in RA. Similar observations were reported 
in patients with acute stroke [9]. By performing linear logistic regression analysis, TAWF, 
sandwich-like texture and bone thickness all correlated with age. Interestingly, TAWF and the 
special trilayer texture also correlated with serum OPG levels. OPG was the only bone 
biomarker that exerted association with TAW characteristics. Finally, left TAW bone thickness 
inversely correlated with total hip and femoral neck BMD and T-scores indicating, that locally 
increased TAW thickness may be seen in patients with more pronounced generalized 
osteoporosis. We also performed multivariate logistic regression analysis. Age was independent 
prognostic factor for TAWF and sandwich-like texture. Again, serum OPG was an independent 
predictor of TAWF in RA patients. With age, the temporal bone gets thicker leading to reduced 
detectability of the foramen. Similar correlations were found in other studies carried out in the 
general population [6] and in stroke patients [9]. TAW thickness was inversely correlated with 
hip and femoral neck BMD. RA, especially active disease, has been associated with generalized 
bone loss [10-13] primarily due to inflammatory bone resorption [14, 15]. In stroke patients, 
there was no association between TAWF and BMD, however temporal bone heterogeneity, 
similarly to our results, was inversely associated with BMD [9]. OPG is a decoy receptor and 
inhibitor of RANK-RANKL-mediated inflammatory bone loss [16]. In RA, OPG production 
may be a counter-regulator of bone resorption [16, 17] and both anti-TNF [18] and anti-IL-6 
biologics [19] increase circulating OPG levels. In our study, TAWF and heterogeneous texture 
were correlated with higher OPG levels.   
In conclusion, TAWF is more prevalent in RA patients than in the general population. 
We can hypothesize that as TAWF and TAW thickness have been associated with increased 
production of OPG and lower hip BMD and T-score, respectively, it is likely, that secondary 
generalized osteopenia/osteoporosis observed in a great proportion of RA patients, especially 
in those with more severe disease [10, 11] may induce the counter-regulatory release of OPG. 
OPG, in turn, may also stimulate bone apposition in the temporal bone surrounding the TAW 
leading to TAWF, increased thickness and, due to more rapid burn turnover, heterogeneous 
bone texture [18, 19]. Clinically, the detection of TAW is not only important to understand 
temporal bone homeostasis that may also reflect systemic bone metabolism, but also to select 
patients suitable for TCD assessments. More studies to be carried out in large number of patients 
are necessary to further characterize TAWF, features of the temporal bone and their relation to 
bone biology.  
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Table 1. General characteristics and laboratory markers of RA patients 
 RA patients 
n 62 
age (years) 60.7±9.5 
disease duration (years) 11.5±7.6 
RF positivity (%) 45 (74%) 
anti-CCP positivity (%) 30 (75%) 
MTX duration (years) 6.5±3.9 
MTX dose (mg/week) 14.9±5.5 
Low-dose corticosteroid (n) 32 
Biologic-treated (n) 42 
MTX-treated (n) 20 
biologic duration (years) 5.2±1.9 
DAS28 2.46±0.82 
ESR (mm/h) 17.42±14.50 
hsCRP (mg/l) 5.35±7.83 
L1 BMD (g/cm²) 0.872±0.131 
L1 T-score -1.25±1.18 
L2-4 BMD (g/cm²) 0.922±0.132 
L2-4 T-score -1.13±1.24 
Femoral neck BMD (g/cm²) 0.698±0.118 
Femoral neck T-score -1.41±0.94 
Total hip BMD (g/cm²) 0.825±0.140 
Total hip T-score -0.92±1.22 
osteocalcin (OC, µg/l) 18.53±6.57 
β-CTX (µg/l) 0.302±0.140 
P1NP (µg/l) 50.74±18.70 
25-OH-vitD3 (nmol/l) 58.20±28.16 
PTH-I (pmol/l) 4.14±1.58 
sclerostin (SOST, pmol/l) 31.99±10.52 
osteoprotegerin (OPG, pmol/l) 7.49±3.35 
sRANKL (pmol/l) 0.127±0.102 
OPG/RANKL ratio 214.16±620.80 
 
  
Table 2. TAW features in RA patients and controls 
 
 RA patients Controls p 
TAW failure on either side (%) 54.8 22.0 <0.001 
„Trilayer” (sandwich) texture 53.0 2.9 <0.001 
TAW thickness – right (mm) 
- left (mm) 
3.58±1.43 
4.16±1.56 
2.92±1.22 
2.90±1.16 
NS 
0.001 
 
  
Table 3. Correlations between various TAW features in RA patients (n=62) 
 
Parameter 1 Parameter 2 R value p value 
 
Right TAW 
TAWF thickness 0.811 <0.001 
TAWF heterogeneous texture 0.712 <0.001 
thickness heterogeneous texture 0.569 <0.001 
    
Left TAW 
TAWF thickness 0.768 <0.001 
TAWF heterogeneous texture 0.791 <0.001 
thickness heterogeneous texture 0.457 0.002 
    
Right vs Left TAW 
TAWF (R) TAWF (L) 0.634 <0.001 
thickness (R) thickness (L) 0.754 <0.001 
texture (R) texture (L) 0.721 <0.001 
 
 
  
Table 4. Correlations between TAW features and other characteristics in RA patients (n=62)* 
 
 Odds [Exp(B)] (CI 95%), p value 
side right left both 
TAW failure/score 
age (years) 1.1 (1.025-1.181), p=0.008 1.190 (1.079-1.311), p<0.001 1.106 (1.028-1.189) p=0.007 
osteoprotegerin (OPG, pM)  1.690 (1.123-2.542), p=0.012  
TAW texture (sandwich-like) 
age  0.081 (0.023-0.140), p=0.007 - 
osteoprotegerin (OPG, pM) 0.807 (0.647-1.005), p=0.045 0.653 (0.462-0.922), p=0.016 - 
TAW thickness 
age 0.063 (0.008-0.118), p=0.025 0.081 (0.023-0.140), p=0.007 - 
femoral neck BMD (g/cm²)  -5.708 (-9.995- -1.420), p=0.010 - 
femoral neck T-score  -0.633 (-1.109- -0.157), p=0.010 - 
total hip BMD (g/cm²)  -4.037 (-7.110- -0.963), p=0.011 - 
total hip T-score  -0.493 (-0.871- -0.116), p=0.012 - 
*Linear binary logistic regression. Table only shows statistically significant correlations. See text for 
abbreviations.  
 
 
  
Table 5. Independent prognostic factors for TAW failure in RA (n=62)* 
 
 Odds [Exp(B)] (CI 95%), p value 
side right left both 
TAW failure/score 
age (years)  1.531 (1.051-2.231), p=0.026  
osteoprotegerin (OPG, pM)  1.154 (1.005-1.325), p=0.012  
TAW texture (sandwich-like) 
age  0.081 (0.023-0.140), p=0.007 - 
*Multivariate binary logistic regression. Table only shows statistically significant correlations. See text for 
abbreviations.  
 
